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Summary: The identification of CD25 and subsequently Forkhead box
protein 3 (Foxp3) as markers for regulatory T cells (Tregs) has revolu-
tionized our ability to explore this population experimentally. In a sim-
ilar vein, our understanding of antigen-specific Treg responses in vivo
owes much to the fortuitous generation of T-cell receptor (TCR)-
transgenic Tregs. This has permitted tracking of Tregs with a defined
specificity in vivo, facilitating analysis of how encounter with cognate
antigen shapes Treg homeostasis and function. Here, we review the
key lessons learned from a decade of analysis of TCR-transgenic Tregs
and set this in the broader context of general progress in the field. Use
of TCR-transgenic Tregs has led to an appreciation that Tregs are a
highly dynamic proliferative population in vivo, rather than an anergic
population as they were initially portrayed. It is now clear that Treg
homeostasis is positively regulated by encounter with self-antigen
expressed on peripheral tissues, which is likely to be relevant to the
phenomenon of peripheral repertoire reshaping that has been described
for Tregs and the observation that the Treg TCR specificities vary by
anatomical location. Substantial evidence has also accumulated to sup-
port the role of CD28 costimulation and interleukin-2 in Treg homeo-
stasis. The availability of TCR-transgenic Tregs has enabled analysis of
Treg populations that are sufficient or deficient in particular genes,
without the comparison being confounded by repertoire alterations.
This approach has yielded insights into genes required for Treg func-
tion in vivo, with particular progress being made on the role of ctla-4 in
this context. As the prospect of manipulating Treg populations in the
clinic becomes reality, a full appreciation of the rules governing their
homeostasis will prove increasingly important.
Keywords: Tregs, immune regulation, tolerance, TCR-transgenic, Treg proliferation,
Treg function
Introduction
Despite the theoretical capacity to form >1015 unique ab
T-cell receptors (TCRs) (1), humans contain only around
1012 T cells (2), indicating that only a small fraction of
potential TCR specificities is deployed at any one time.
Protective immunity against a wealth of unpredictable infec-
tions therefore relies on a high level of TCR cross-reactivity
(3, 4) that is beginning to be documented experimentally
(5). In light of this understanding, the simplistic notion that
T cells are purged of self-reactive specificities during thymic
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development becomes untenable; removing all cells with the
potential to cross-react with self-antigens would leave us
with a dangerously narrow protective repertoire. In parallel
with this realization, support has grown for the existence of
additional tolerance mechanisms that might compensate for
the inherent limitations of negative selection. Indeed, the
concept of dominant tolerance, whereby T cells with regula-
tory function actively control the self-reactive T cells that
enter the peripheral repertoire, is now well recognized (6–
10). Considerable research effort has focused on unraveling
the identity and characteristics of the regulatory T-cell popu-
lation(s) and a large body of knowledge has now been gath-
ered in this area. One approach that has proved informative
is the use of regulatory T cells (Tregs) expressing transgenic
TCRs, permitting analysis of the antigen-specific activation
of this population in vivo. Here, we review some of the
insights that have been made using this approach and how
it has shaped our understanding of Treg biology.
TCR-transgenic Tregs: a window on Treg thymic
selection
While the focus of this review is the homeostasis and func-
tion of Tregs in the periphery, it is important to first briefly
consider Treg thymic selection. Study of TCR-transgenic
Tregs has been formative in shaping many of our current
ideas about how Tregs are generated intrathymically. In fact,
the important observation that thymocytes could be directed
to differentiate into Treg in response to thymic self-antigen
expression was made using a TCR-transgenic system with
specificity for influenza hemagglutinin (HA) (11). This par-
adigm was subsequently shown to hold true for other trans-
genic TCR/cognate antigen double-transgenic systems (12,
13). For example, DO11.10 TCR-transgenic mice on a
recombinase activating gene-deficient (RAG/) background
fail to develop Tregs (14); however, transgenic provision of
ovalbumin (OVA) in the thymus permits Treg generation in
these mice (13). In the latter experiments, OVA was
expressed under the control of the rat insulin promoter
(rip-mOVA), which is known to drive expression of
functionally significant levels of OVA intrathymically (15),
like the endogenous insulin promoter (16). Interestingly,
RAG-sufficient DO11.10 TCR-transgenic mice were found to
select a small number of Tregs in the absence of thymic
OVA expression (13, 14, 17), but these Tregs were
enriched for endogenous TCRa chains (13, 17) consistent
with the use of an alternative TCR to support their
differentiation. Thus, T cells with TCRs that cannot
recognize intrathymic antigen (DO11.10/RAG/) were
precluded from differentiating into Treg, but provision of
relevant antigen in the thymus (DO11.10+ rip-
mOVA+ RAG/), or the potential to recognize intrathymic
antigen using non-transgenic TCR chains (DO11.10/RAG+)
permitted Treg generation.
Leading on from the use of TCRs specific for model anti-
gens, a subsequent wave of experiments employed trans-
genic TCRs that were derived from naturally occurring Tregs
(18, 19). These experiments reinforced the role of TCR
specificity in Treg thymic selection and suggested a model
in which intraclonal competition limits the number of T
cells of a given specificity that can develop into Tregs (18,
19). Whether such niche constraints restrict Treg differentia-
tion in the context of a diverse repertoire of precursors
remains less clear (20).
Tregs as a highly proliferative population
Lack of Treg anergy in vivo
Early analysis of mature Tregs using in vitro assays identified
a striking lack of proliferation following TCR engagement,
leading to the characterization of this population as naturally
anergic (14, 21, 22). In fact, anergy came to be known as
one of the defining features of Treg populations. The gener-
ation of mice bearing TCR-transgenic Tregs provided the
first opportunity to monitor Treg behavior in vivo, using clo-
notypic antibodies to track a discrete cohort of adoptively
transferred Tregs responding to a specific antigen. Surpris-
ingly, this approach revealed a remarkable capacity for Tregs
to proliferate when responding to cognate antigen in vivo.
Accordingly, OVA-specific Tregs mounted a robust prolifera-
tive response to OVA protein in incomplete Freund’s adju-
vant (IFA) (13) (Fig. 1), while HA-specific TCR-transgenic
Tregs proliferated and accumulated in the draining lymph
node (LN) following subcutaneous immunization with HA
peptide in IFA (23).
The Tregs utilized in the above experiments derived from
double-transgenic mice expressing the TCR transgene in
conjunction with its relevant antigen under ubiquitous
(phosphoglycerate kinase-HA) or tissue-specific (rip-mOVA)
control. In both sets of double-transgenic mice, CD25+ cells
expressing the TCR transgene were detectable in the thymus
and peripheral lymphoid organs (13, 23) and exhibited typ-
ical Treg features including the presence of intracellular
cytotoxic T-lymphocyte antigen-4 (CTLA-4) and low levels
of surface interleukin 7 receptor a (IL-7Ra) expression
(13). These experiments were performed prior to the
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development of Forkhead box protein 3 (Foxp3) staining
protocols, but several lines of evidence argued against the
CD25+ cells being activated conventional T cells rather than
Tregs. Notably, the extensive proliferative response of this
population was uncoupled from production of cytokines
such as IL-2, interferon-c (IFNc), and IL-4 (13, 23), and
instead IL-10 production was observed in one of the studies
(23). In addition, while TCR-transgenic conventional T cells
upregulated CD40L following antigen encounter,
this response was completely lacking in the TCR-
transgenic CD25+ fraction (13). Perhaps, the most compel-
ling demonstration that the TCR-transgenic CD25+ cells
were in fact Tregs was that despite their capacity to prolifer-
ate in vivo, they were strictly anergic when assessed in vitro
and elicited robust suppression in standard co-culture assays
(13, 23). Thus, TCR-transgenic Tregs recapitulated the in
vitro behavior previously ascribed to this subset, yet permit-
ted new insights into the antigen-responsiveness of this
population in vivo.
In addition to responding to protein antigen emulsified in
adjuvant, TCR-transgenic Tregs were also shown to proliferate
following provision of peptide-pulsed bone marrow-derived
dendritic cells (DCs) (24). In the latter study, subcutaneous
injection of OVA-pulsed DCs triggered the proliferation of
OVA-specific Tregs in the draining LN, leading to an eight- to
10-fold expansion over the course of 3 days. Elegant studies
in which mice were engineered to transgenically express TCR
chains from a scurfy mouse-derived CD4+ T cell also
revealed robust proliferation within the Foxp3+ compartment
(25), demonstrating that the phenomenon extended
beyond the extensively utilized TCRs specific for model
antigens.
Validation that TCR-transgenic Tregs were accurately mim-
icking the proliferative capacity of normal polyclonal Tregs
came from experiments in which CD4+ CD25hi CD62Lhi
cells were carboxyfluorescein succinimidyl ester (CFSE)-
labeled and adoptively transferred into congenically distinct
recipient mice (26). Thirty-five days later, approximately
70% of the donor Tregs had divided, most of them more
than six times. Interestingly, the CD25hi phenotype of the
injected Treg population was remarkably stable, with
approximately 90% of the cells retaining high CD25 expres-
sion even 70 days following transfer. This is consistent with
the subsequent demonstration that Treg Foxp3 expression is
also very stable under physiologic conditions (27). Bromo-
deoxyuridine (BrdU) labeling experiments further supported
the notion that Tregs represent a highly proliferative popula-
tion in normal mice, with Tregs consistently incorporating
higher levels of this thymidine analog than conventional
T cells (26, 28). In line with this, the proportion of
CD4+ Foxp3+ Tregs staining positive for the proliferation
marker Ki67 is consistently higher than that of the conven-
tional T-cell fraction (Fig. 2), and is still higher if Tregs are
rendered deficient in the lipid phosphatase PTEN (29).
Further insight into the biochemical control of Treg prolifer-
ation was recently gleaned by analysis of animals in which
raptor, an obligatory component of the mammalian target of
rapamycin complex 1 (mTORC1) complex, was selectively
deleted in Tregs (30). Raptor-deficient Tregs showed a
striking lack of proliferation, compared with control Tregs,
when cell trace labeled and adoptively transferred into nor-
mal recipients. These experiments established a critical
role for raptor/mTORC1 signaling in Treg proliferation,
with the mevalonate pathway proving particularly important
(30).
Experiments examining the proliferative capacity of
human Tregs have largely recapitulated findings in mice
(Fig. 2). Despite in vitro anergy (31, 32), when analyzed ex
vivo, on average 22% of blood CD4+ CD25+ CD127lo Foxp3+
T cells stained positive for the proliferation marker Ki67
compared with 5% of the CD4+ CD25int cells and 2% of the
CD4+ CD25 cells (33). This high proliferative capacity was
maintained over a period of 3–4 months in longitudinally
tracked individuals (33). Detailed characterization of human
Fig. 1. Proliferation of T-cell receptor-transgenic Tregs in vivo after
immunization with cognate antigen. Conventional or regulatory T
cells were purified from DO11 9 rip-mOVA mice, CFSE-labeled, and
adoptively transferred into BALB/c recipients. Recipient mice were
injected subcutaneously with PBS or OVA emulsified in incomplete
Freund’s adjuvant. Three days later, the proliferation of DO11+ T cells
in draining LN was assessed.
© 2014 The Authors. Immunological Reviews Published by John Wiley & Sons Ltd.
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Treg populations by the Sakaguchi group has clarified that
the proliferative fraction resides within the
CD45RA Foxp3hi ‘activated Treg’ population (34). Interest-
ingly, recent analysis indicates that Tregs isolated from
human secondary lymphoid organs show evidence of an
even greater proliferative capacity than those found in blood,
with approximately 60% staining positive for Ki67 compared
with around 20% in blood-derived Tregs (35). Collectively,
these studies have radically changed our view of Tregs from
an anergic and unresponsive population to a highly dynamic
one, equipped to respond rapidly to homeostatic and anti-
genic cues (36).
Treg proliferation in infection, autoimmunity, and cancer
In addition to proliferating in the steady state, it is now well
established that a variety of stimuli can enhance Treg
proliferation. These include a wide range of immunological
perturbations including exposure to infectious agents. For
example, it has been demonstrated that Tregs proliferate and
accumulate at sites of Leishmania major infection, with up to
80% of Tregs from such sites showing the capacity to
respond specifically to Leishmania-infected DCs ex vivo (37).
Similarly, infection of mice with Mycobacterium tuberculosis
(Mtb) was shown to trigger proliferation of pathogen-
specific TCR-transgenic Tregs (38). Subsequent studies by
the same group used tetramers to show that endogenous
Mtb-specific Tregs also proliferated and expanded in the
pulmonary lymph node of infected mice. Importantly, Treg
accumulation was short-lived due to selective loss of these
cells via an IL-12 and Tbet-dependent mechanism, thereby
lifting regulation during the latter stages of infection (39).
Viruses can also trigger the expansion of Tregs (40–42),
and in one case, this was shown to occur by a superanti-
gen-dependent pathway (43). Similarly, Tregs are known to
proliferate in response to helminths with the proportion of
Foxp3+ Tregs incorporating BrdU in the pleural cavity
increasing from approximately 20% to over 50% following
Litomosoides sigmondontis infection (44). In a separate study,
Tregs expanded in response to Heligmosomoides polygyrus infec-
tion in an inducible costimulatory (ICOS)-dependent man-
ner, and this was shown to reflect a role for ICOS in
supporting the survival of divided Tregs, rather than an
obligate role in proliferation itself (45).
In the context of autoimmune disease, Tregs have been
shown to exhibit heightened proliferation in the peripheral
blood of individuals with systemic autoimmunity (46) and
at the site of inflammation in tissue-specific autoimmunity.
For example, Tregs from the synovial fluid of arthritis
patients showed substantially higher proliferation than those
in peripheral blood (47), and increased Treg proliferation
has been documented in the inflamed CNS of mice with
EAE (48) and the pancreas of BDC2.5 NOD mice (49). In
the latter model, mice express a transgenic TCR comprising
rearranged TCRa and b genes from a diabetogenic T-cell
clone isolated from a non-obese diabetic (NOD) mouse
(50). Both Treg and effector T cells infiltrate the islets in
BDC2.5 NOD mice, and disease incidence is low unless
Treg development is precluded by introduction of the
Fig. 2. Analysis of mouse and human Treg proliferation by Ki67 staining. Tregs from the LN of a BALB/c mouse or from human blood were
stained with Ki67. Murine Tregs were defined as CD4+ Foxp3+. Human Tregs were defined as CD4+ CD127low Foxp3+.
© 2014 The Authors. Immunological Reviews Published by John Wiley & Sons Ltd.
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Foxp3 scurfy mutation (51). Tregs infiltrating the pancreas
of BDC2.5 NOD mice were shown to incorporate higher
levels of BrdU than conventional T cells present at this site
(49). Consistent with this observation, Tregs infiltrating the
islets in non-TCR-transgenic NOD mice showed increased
staining for Ki67 compared with conventional T cells;
intriguingly, this was the case in new onset disease but not
in prediabetic animals (52). The loss of pancreas-
resident Tregs following administration of the chemothera-
peutic alkylating agent cyclophosphamide (53) may in part
reflect its ability to efficiently inhibit Treg proliferation
(54).
Tregs have long been recognized to be overrepresented in
tumors (55), prompting interest in their proliferation at
such sites. In the context of B16F10 and 4T1 tumors, analy-
sis of tumor-draining LNs showed that Tregs proliferated
substantially more than effector CD4+ or CD8+ T cells (56).
Tregs infiltrating brain tumors in a mouse model of glio-
blastoma showed markedly increased proliferation compared
with their Foxp3-negative counterparts (57). Furthermore,
analysis of carcinogen-induced sarcomas in mice revealed
that over 60% of the tumor-infiltrating Tregs incorporated
BrdU following a 3-day pulse, clearly illustrating the high
proliferative potential of the tumor-resident Treg population
(58). Expansion of intratumoral Tregs is thought to reflect
the marked proliferation of a few dominant clones (59) and
could be driven in part by the high levels of TGFb that typi-
fies the tumor microenvironment (60) or by factors associ-
ated with angiogenesis such as vascular endothelial growth
factor (61).
The discovery that Tregs can proliferate in the steady state
has been rapidly followed by an appreciation that this pro-
liferative response can be significantly augmented in a vari-
ety of medically relevant settings including infection,
autoimmunity, and cancer. Such expansion could potentially
serve to bolster the Treg population during immunological
insults, such that they are poised to efficiently terminate
immune responses (62).
Factors controlling peripheral Treg homeostasis
Role of TCR signaling in shaping Treg homeostasis
A major force that shapes the homeostasis of Treg populations
in the periphery is signaling through the TCR. The seeds of
this idea were sown by Peter McCullagh (63), who hypothe-
sized that within any given T-cell clone, both ‘high’ and ‘low’
pathogenicity cells are selected in the thymus, with the latter
able to regulate the pathogenicity of the former. Importantly,
the low pathogenicity (regulatory) clones were postulated to
have a short duration of survival following release from the
thymus unless exposed to their specific ligand (63). The
experimental basis for McCullagh’s hypothesis was the obser-
vation that temporary removal of the thyroid gland in gestat-
ing lambs triggered its destruction upon re-implantation, but
rejection did not occur if part of the gland was allowed to
remain in the animal (64). Further support for the notion that
Treg homeostasis was controlled by access to peripheral
self-antigen (Fig. 3) emerged from studies in rats; ablation of
thyroids in utero rendered peripheral CD4+ T cells incapable of
preventing thyroid autoimmunity, while preserving their
Fig. 3. Role of peripheral self-antigen in Treg homeostasis – 2 decades of progress. (i) Early experiments (1989) in fetal lambs showed that
the continued presence of the thyroid gland was necessary for maintenance of immunological tolerance toward this organ. The cell type
mediating such tolerance was not defined. (ii) Studies in the rat (1999) showed that ablation of the thyroid gland compromised the ability of
peripheral CD4+ T cells to regulate autoimmune thyroiditis. (iii) Experiments in mice (2003, 2004, 2009) showed that Tregs proliferate in
response to tissue-expressed self-antigen; Tregs isolated from draining LNs had a heightened capacity to regulate autoimmune organ destruction
in a manner that was lost upon organ ablation.
© 2014 The Authors. Immunological Reviews Published by John Wiley & Sons Ltd.
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capacity to control other autoimmune diseases (65). The
implication of these data is that CD4+ T cells with regulatory
activity fail to expand to a sufficient frequency or fail to sur-
vive, if denied the opportunity to encounter relevant autoanti-
gen in the periphery.
The advent of TCR-transgenic Tregs permitted the direct
assessment of the role of peripheral self-antigen in control-
ling Treg homeostasis. CFSE-labeled OVA-specific (13) or
HA-specific (26) Tregs were adoptively transferred into
mice expressing the relevant antigen as a tissue-specific self-
protein, and the proliferative response in the draining LN
was assessed a few days later. In both cases, antigen expres-
sion was directed to the pancreatic islets through use of the
rat insulin promoter, and the antigen-specific Tregs were
demonstrated to proliferate specifically in the pancreatic LNs
but not in non-draining LNs (13, 26) (Fig. 3). Importantly,
the absolute number of OVA-specific Tregs in the draining
LN was higher after adoptive transfer into mice expressing
OVA as a self-antigen compared with antigen-negative litter-
mates (13), consistent with a role for peripheral antigen in
positively regulating Treg homeostasis. Similarly, Tregs
endowed with the capacity to regulate autoimmune ovarian
disease were found to be concentrated in the ovary-draining
LN (66). In fact, it was shown for a range of organ-specific
autoimmune diseases that Treg activity was enriched in the
autoantigen-draining LN in a manner that could be abol-
ished by selective autoantigen ablation (67). These data add
a CD4+ CD25+ Foxp3+ dimension to the thyroid ablation
studies performed a decade earlier (65) that examined the
regulatory capacity of the CD4+ population as a whole
(Fig. 3). As LNs draining the site of autoantigen expression
have been shown to be key sites for the priming of autore-
active pathogenic T cells (68, 69), it appears that regional
LNs are actively involved in both the generation and sup-
pression of tissue-specific autoimmune responses.
The considerable proliferative capacity of Tregs in vivo begs
the question of which cell type supports such a response. In
this regard, most attention to date has focused on DCs. DCs
have been shown to be capable of driving Treg proliferation
both in vitro and in vivo (24), particularly those bearing a
CD8a-negative phenotype (70). DCs are also required for the
expansion of Tregs in the setting of chronic LCMV infection
(43). Ablation of DCs in mice expressing diphtheria toxin
receptor under the control of the CD11c promoter signifi-
cantly reduced Treg proliferation (71), although it should be
noted that mice constitutively lacking DCs from birth showed
only a marginal reduction in Treg numbers (72). Neverthe-
less, augmenting the DC population by exogenous Flt3 ligand
administration significantly increases the Treg population,
even in thymectomized mice, arguing for effects on periph-
eral homeostasis rather than thymic generation (73). Further
support for an influential role for DCs in Treg homeostasis
derives from the observation that Treg numbers correlate with
the number of major histocompatibility complex (MHC) class
II-expressing DCs (74). The requirement for DCs to express
MHC class II to influence Treg homeostasis (74) is consistent
with a role for Treg TCR signaling and fits with the observa-
tion that Tregs rendered p56(Lck)-deficient are impaired in
their proliferative response in vivo (75).
The above observations suggest a model in which the size
of the peripheral Treg niche is set by the availability of MHC
class II-expressing DCs bearing relevant peptides. This model
is supported by the demonstration that wildtype Tregs, pre-
sumably selected on a diverse array of peptides in the thymus,
failed to divide in the periphery if transferred to mice in the
which the MHC class II molecules were loaded with a single
peptide, CLIP (76). In contrast, Tregs selected within a thymic
environment expressing only CLIP proliferated to a greater
extent in the periphery of these animals, consistent with hav-
ing more Tregs-bearing TCRs that recognize this peptide
(76). Artificially supplementing TCR engagement by adminis-
tration of anti-CD3 permits enlargement of the Treg popula-
tion by driving additional Tregs into cycle, offering further
support for the involvement of TCR signaling in setting the
size of the peripheral Treg niche (77).
The proliferation (13, 26) and selective accumulation (66,
67, 78) of Tregs in LN draining sites of self-antigen expres-
sion implies that Treg with a given TCR specificity is not uni-
formly distributed throughout the body but rather are subject
to local homeostatic control. In line with this idea, by
sequencing TCRa chains in mice with a fixed TCRb chain, the
Hsieh laboratory (79) showed that the TCR repertoire of
Tregs varies substantially according to anatomical location.
This variation differs from similar analysis of the naive T-cell
population, which revealed little repertoire skewing between
anatomical sites (79), consistent with the free recirculation of
naive T cells between secondary lymphoid organs.
Lymphoid organs aside, there is an increasing apprecia-
tion that Tregs can be found embedded within tissues them-
selves (e.g. within adipose tissue) (80) and that the
repertoire of these Tregs may be distinctive (81). Now that
the existence of tissue-resident memory T cells has been
clearly documented in humans (82), understanding whether
discrete populations of Treg police each of these niches and
defining the rules governing the maintenance of such popu-
lations will be an important aim.
© 2014 The Authors. Immunological Reviews Published by John Wiley & Sons Ltd.
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Role of IL-2 in peripheral Treg homeostasis
It is well accepted that the cytokine most influential in Treg
homeostasis is IL-2. The immunoregulatory role of this
cytokine first came to light with the observation that mice
deficient in IL-2 signaling exhibit polyclonal expansion of
lymphocytes with tissue infiltration, autoantibody produc-
tion, anemia, and in some cases, inflammatory bowel dis-
ease (83–85). Available evidence, albeit limited, suggests
that IL-2Ra deficiency also causes a similar phenotype in
humans, with lymphadenopathy, anemia, and multi-organ
lymphocytic infiltration (86). The prospect that this might
reflect impairment of regulatory cells was raised by mixing
experiments in which the presence of IL-2-sufficient T cells
curbed the uncontrolled expansion of those rendered IL-2
deficient (87). The advent of CD25 as a marker of the Treg
population permitted a more refined version of this experi-
ment in which CD4+ CD25+ cells were shown to prevent
lethal autoimmunity following adoptive transfer into IL-
2Rb-deficient mice (88). Along similar lines, CD4+ CD25+
cells prevented disease caused by the introduction of IL-
2Ra/ bone marrow into rag-deficient hosts (89). Thus,
the dysregulated immunity in mice lacking IL-2 signaling
could be attributed to a failure to maintain CD4+ CD25+
Tregs.
The central role for IL-2 in Treg homeostasis and meta-
bolic fitness has since been clearly demonstrated (90, 91).
IL-2 has been shown to reinforce qualitative aspects of the
Treg program in addition to simply conferring a survival
advantage, as Tregs that lack IL-2 signaling express low lev-
els of numerous markers associated with the Treg phenotype
(CTLA-4, CD39, CD73) (92). Interestingly, the role of the
microRNA miR155 in promoting Treg homeostasis is
thought to reflect its ability to inhibit SOCS1, thereby sensi-
tizing Treg to IL-2 signaling (93). Along similar lines, Tregs
are characterized by low SOCS3 expression, compared with
conventional T cells, further increasing their IL-2 respon-
siveness (94).
Elegant experiments using bone marrow chimeric mice
revealed that the size of the peripheral CD4+ CD25+ Treg
compartment is directly related to the number of conven-
tional T cells capable of producing IL-2 (95). Consistent
with this scenario, neutralizing IL-2 with antibodies reduces
the steady state in vivo proliferation of Treg in normal mice
(71, 96). Conversely, acute Treg ablation triggers a dramatic
increase in the proliferation of those Tregs remaining (from
approximately 20% to 70% Ki67+), and this increase corre-
lates with increased plasma levels of IL-2 (97). The pivotal
role of IL-2 in setting the size of the peripheral Treg com-
partment has led to therapeutic IL-2 administration being
tested in mouse models of autoimmunity (52, 98, 99) and
subsequently in several human clinical trials (100–103).
The coupling of Treg numbers to conventional T-cell IL-2
production (95) laid the foundation for the notion that Treg
homeostasis and function can be ‘boosted’ by the conven-
tional T-cell compartment (104). Accordingly, experiments
with TCR-transgenic T cells and Tregs sharing the same
specificity revealed that T-cell activation triggers a feedback
loop whereby suppressive capacity is augmented hand
in hand with the conventional T-cell response (104).
One manifestation of this is the striking observation that
when conventional T cells are activated by antigen in vivo,
the early wave of IL-2 produced serves primarily to activate
Treg in the locality (105). However, IL-2 cannot explain the
whole of the boost effect, and a role for TNFa in augment-
ing Treg proliferation was also identified (104).
Intriguingly, recent data suggest that in certain settings, Treg
function may also be boosted by engagement of their
surface Nrp1 by the ligand Sema4a (106). The feedback
loops operating to ensure appropriate suppression during
immune responses are only now beginning to emerge and
alterations in these may well underlie the immune imbal-
ance observed in the context of autoimmunity.
Role of CD28 in Treg homeostasis
One of the earliest pathways identified in our quest to
understand Treg homeostasis was costimulation through
CD28. The surprising observation that autoimmune diabe-
tes was exacerbated in mice lacking CD28, or its ligands
CD80 and CD86, was reconciled by the discovery that
Tregs were dramatically reduced in these animals (107).
Tregs were defined on the basis of CD25 expression in
the latter study, but the deficit of Tregs in CD28 knockout
mice was later confirmed using Foxp3 staining (108). The
proliferation of CFSE-labeled polyclonal Treg adoptively
transferred into syngeneic mice could be blocked by anti-
bodies to CD80 and CD86 (109), and this was associated
with a decrease in Treg number and also a loss in the
intensity of CD25 expression (109). The latter was subse-
quently attributed to CD28 deficiency in the conventional
T-cell compartment, presumably resulting in decreased IL-
2 availability (110). The contribution of NF-jB-inducing
kinase (NIK) to CD28 signaling (111) may provide a
potential explanation of why NIK-deficient Tregs exhibit a
defect in peripheral homeostasis (112).
© 2014 The Authors. Immunological Reviews Published by John Wiley & Sons Ltd.
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Further evidence for the importance of costimulatory signals
in Treg homeostasis arose from analysis of CTLA-4-deficient
mice that have a lymphoproliferative phenotype (113, 114)
driven by excessive CD28 signaling (115). These animals
exhibit increased Treg proliferation and an augmented Treg
population (116, 117) consistent with the role of CD28 in
promoting Treg proliferation. Likewise, short-term blockade
of CTLA-4 in wildtype mice increases Treg proliferation (116,
118, 119), an effect that is recapitulated by administration of
anti-CTLA-4 antibody to humans (120). Given the impor-
tance of CD28 in driving Treg proliferation and the role of
CTLA-4 in limiting CD28 engagement (121–123), the Treg
proliferation induced in CTLA-4/ mice and by anti-CTLA-4
antibody likely results from enhanced CD28 signaling due to
increased availability of costimulatory ligands.
The recent generation of mice in which CD28 can be in-
ducibly deleted has allowed further exploration of the role
of this receptor in Treg homeostasis (110). Accordingly,
tamoxifen-induced CD28 deletion was shown to trigger a
dramatic reduction in Treg frequencies as early as 1 week
after treatment (110). The decrease in Tregs was also
observed in thymectomized mice and was associated with
reduced Ki67 staining, implying a crucial role for CD28 in
peripheral Treg maintenance. To home in on the role of
CD28 specifically in Tregs, the Turka group (124) generated
an animal model in which CD28 was selectively deleted
from Foxp3-expressing cells. Mice with a floxed CD28 gene
were crossed with Foxp3-YFP-Cre mice, such that Foxp3
promoter activity was linked both to yellow fluorescence
protein (YFP) expression and excision of the floxed CD28
gene. A decrease in the proportion of Foxp3+ Treg was
observed within the CD4 single-positive population in the
thymus (124), in line with the known role of CD28 in pro-
moting thymic selection of Tregs (108, 109, 125). How-
ever, the peripheral Treg compartment was replete in these
animals, consistent with the notion that peripheral Treg
homeostasis can be uncoupled from thymic output (89).
Intriguingly, the animals lacking CD28 in Tregs developed
autoimmune symptoms over time, primarily focused on the
liver and skin, supporting a requirement for CD28 in Treg
function (124). In female mice heterozygous for Foxp3-Cre
in which approximately half the Tregs delete CD28 (due to
random inactivation of the X-chromosome), CD28-depen-
dent effects on Treg homeostasis were revealed. Accord-
ingly, the CD28-sufficient Tregs in these animals
incorporated significantly more BrdU than those lacking
CD28 in the same animal (124). The competitive advantage
conferred by Treg CD28 expression was further revealed by
mixed bone marrow transfers into irradiated recipients:
when analyzed 6 months later, the entire Treg compartment
appeared to derive from CD28-sufficient rather than CD28-
deficient cells, while the rest of the hematopoietic compart-
ment remained of mixed origin (124).
The early studies showing that DCs could drive Treg
proliferation in vivo highlighted the importance of CD86/
CD80 expression for this function; OT-II TCR-transgenic
Treg proliferated robustly in the presence of OVA peptide-
pulsed lipopolysaccharide-matured DCs, but the response
was reduced by around 70% if the DCs derived from
CD80/CD86 knockout mice (24). The key roles for DCs
(71, 73, 74) and the CD80/CD86 axis (107, 109) in main-
taining Treg homeostasis begged the question of whether
DCs represent the critical source of costimulatory ligands for
Treg in vivo. This issue was elegantly explored by experi-
ments in which DC-deficient (CD11c:DTA) bone marrow
and CD80/CD86-deficient bone marrow were mixed and
used to reconstitute lethally irradiated wildtype mice (126).
The only DCs able to develop in the resulting chimeras
lacked expression of CD80 and CD86, but other cell types
(such as B cells) expressed these ligands at normal levels. In
the absence of DC-expressed CD80/CD86, Tregs developed
normally in the thymus, but their numbers were markedly
reduced in the periphery (126). This suggests that DCs are a
crucial source of CD28 ligands for maintaining peripheral
Treg homeostasis.
The role of CD28 in positively regulating Treg homeosta-
sis also appears to hold true in humans (127). Accordingly,
the proliferative response of human Tregs cultured for
6 days with allogeneic mature DCs is largely inhibited by
blocking anti-CD86 antibody (128). In addition, IDO activa-
tion was shown to modulate proliferation of human Tregs
in the context of mixed lymphocyte reaction responses in a
manner dependent on CD80/CD86 (129). Thus, CD28
costimulation represents a primary pathway for promotion
of Treg homeostasis in both mouse and human.
Apoptosis of peripheral Tregs
Given the considerable proliferation of Tregs evident in vivo,
one might expect this population to be continually
increasing in size. As this is not the case, it follows that Treg
proliferation must be countered by apoptosis. Early work by
Taams et al. (32) identified that blood CD4+ CD25+ cells
had lower levels of Bcl2 than their CD25 counterparts and
were more prone to undergo apoptosis upon cytokine
withdrawal. The propensity of murine Tregs to undergo
cytokine-withdrawal apoptosis and the importance of
© 2014 The Authors. Immunological Reviews Published by John Wiley & Sons Ltd.
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common c-chain cytokines in countering this process was
subsequently demonstrated (130). Intriguingly, it has
recently been shown that Foxp3 itself can exhibit pro-apop-
totic activity, increasing the activity of Puma and Bim and
repressing Bcl2 expression in thymic Treg precursors, such
that these cells must compete for cytokine signals to ensure
their survival (131). IL-2 is normally critical for generating
a replete peripheral Treg compartment, but this requirement
can be circumvented if Treg apoptosis is prevented by Bim
deficiency (132).
The importance of apoptosis in setting the size of the
peripheral Treg niche has recently been demonstrated by
the generation of mice that selectively lack the pro-apopto-
tic molecules Bak1 and Bax in Tregs; these mice show
increased peripheral accumulation of Tregs, despite normal
thymic development (97). A surprise finding from this
study was that the anti-apoptotic protein responsible for
promoting survival in the Treg compartment is Mcl-1 (97)
rather than Bcl-2 or Bcl-XL, as has been tacitly assumed for
years. Thus, the decreased level of Bcl2 observed in apop-
tosis-prone Tregs may actually be correlative rather than
causal.
Experiments in mice suggest that the propensity of
Tregs to apoptose may decline with age in a manner that
is associated with decreased Bim expression. The latter
conclusion was based on the observation that Bim levels
were markedly lower in Tregs from 20-month-old mice
compared with 1.5-month-old animals (133); how this
relates to Treg homeostasis in aging humans remains to
be established.
Use of TCR-transgenic Tregs to probe suppressive
mechanisms in vivo
It is increasingly clear that Tregs can call upon a vast array of
mechanisms to maintain dominant tolerance (134, 135).
These are suggested to encompass use of granzyme B (136),
CD73/CD39 (137), CTLA-4 (138, 139), TGFb (140, 141),
IL-10 (142), and IL-35 (143). Tregs have also been demon-
strated to act as an ‘IL-2 sink’ (144–146) and to induce the
expression of enzymes that consume essential amino acids
(147), in both cases depriving conventional T cells of essential
growth factors. Moreover, Tregs are thought to interact with
multiple target populations to effect suppression, including
conventional T cells and antigen-presenting cells.
The role of CTLA-4 in Treg-mediated suppression has
been a matter of contention for more than a decade (108,
148). The issue first came to light after the demonstration
that unlike conventional CD4+ T cells, Tregs constitutively
express CTLA-4 (138, 139, 149). Many approaches have
since been adopted in an effort to clearly define the function
of Treg-expressed CTLA-4, an endeavor that has been
complicated by a lack of clarity on the basic nature of
CTLA-4-mediated inhibition. In addition, the lethal lympho-
proliferative syndrome observed in CTLA-4/ mice (113,
114) has rendered data obtained from these animals difficult
to interpret. However, recent studies using antigen-specific
Tregs have proved insightful. Indeed, our own laboratory
has overcome some of the issues outlined above by using
CTLA-4/ mice expressing the DO11.10 transgenic TCR
on a RAG/ background. As the only TCR expressed in
these mice is directed against a non-self-antigen, T cells
retain a naive phenotype and the severe lymphoproliferative
disease characteristic of CTLA-4/ mice is notably absent
(150). Because Treg development is known to require cog-
nate antigen expression in the thymus, crossing these mice
with those expressing OVA intrathymically due to the rip-
mOVA transgene permits the induction of Tregs with a sin-
gle specificity that can be studied over the long term (116).
An added benefit of this system is that the CD28 pathway is
unaffected, unlike in systems where CTLA-4 immunoglobu-
lin fusion protein (CTLA-4-Ig) or blocking antibodies
against CD80 or CD86 is used to prevent lymphoprolifera-
tive disease.
We utilized Tregs from these mice in an adoptive transfer
model of type-1 diabetes and were able to show that while
CTLA-4-sufficient Tregs were effective at suppressing disease
onset, lack of CTLA-4 expression specifically within the
Tregs compartment prevented suppressive function, with all
recipients rapidly becoming hyperglycemic (116). This was
the first time that Treg populations with an identical speci-
ficity and affinity for antigen (conferred by their DO11.10/
RAG/ status), either expressing or lacking CTLA-4, had
been directly compared. The importance of CTLA-4 expres-
sion for Treg suppression of diabetes was consistent with
the immune dysregulation triggered by Treg-specific dele-
tion of the ctla-4 gene (117) and has since been confirmed
in another diabetes system where disease is driven by T cells
responding to an endogenous pancreatic self-antigen (151).
Precisely how CTLA-4 contributes to Treg suppressive
capacity is still not fully resolved. The first model put
forward to account for CTLA-4-dependent cell-extrinsic
function – that is the ability of CTLA-4 expressed on one
cell to control the response of another cell – involved
CTLA-4 ‘reverse signaling’ through CD80/CD86 on APCs.
CTLA-4-Ig (152) or CTLA-4-expressing Tregs (153) were
shown to activate the suppressive enzyme IDO (indoleamine
© 2014 The Authors. Immunological Reviews Published by John Wiley & Sons Ltd.
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2,3-dioxygenase) in APCs, with the ensuing local trypto-
phan depletion leading to inhibition of T-cell proliferation.
However, others were unable to replicate the induction of
IDO activity in APCs by CTLA-4-Ig (154) and abatacept, a
CTLA-4-Ig fusion protein used clinically, was shown to sup-
press T-cell responses without upregulating IDO (155).
Moreover, when the response of DCs to abatacept was
assessed by Affymetrix microarray, minimal gene changes
were observed and none at all if belatacept, a CTLA-4-Ig
molecule with higher affinity for ligands, was used (156).
Strikingly, a commercially available CTLA-4-Ig protein that
retains full Fc-dependent effector functions induced robust
gene changes in DCs (156). Among the genes upregulated
was IFNc, which had been shown to mediate CTLA-4-Ig-
dependent induction of IDO (152). These findings raise the
possibility that some of the data generated with CTLA-4-Ig
fusion proteins might reflect Fc-dependent signaling rather
than reverse signaling through CD80/CD86.
An alternative model of cell-extrinsic CTLA-4 function
has emerged involving the downregulation of CD80/CD86
on APCs. In common with the reverse signaling model, this
involves the APCs being rendered immunosuppressive, but
this time as a result of impaired costimulatory ligand
expression. The downregulation of CD80/CD86 expression
on APCs by incubation with CTLA-4-expressing cells has
been noted in numerous studies (116, 117, 157–163) and
in many cases is blocked by anti-CTLA-4 antibody (116,
159, 162, 163) or CTLA-4 deficiency (117). In collabora-
tion with the Sansom group (164), we identified a novel
molecular mechanism by which CTLA-4 can downregu-
late CD80/CD86 that involves removal of these ligands
from APCs by a process of trans-endocytosis. Using TCR-
transgenic Tregs, we demonstrated that this process could
occur in vivo, establishing that adoptively transferred Tregs
could acquire GFP-tagged CD86 molecules from host APCs
(164). Using CTLA-4/ TCR-transgenic Tregs that, we had
shown, lack the capacity to regulate diabetes (116), we
demonstrated that ligand trans-endocytosis in vivo was
strictly dependent on CTLA-4 expression (164). Interest-
ingly, we found that activated CTLA-4-expressing conven-
tional T cells were also capable of trans-endocytosis,
consistent with the recent demonstration that conventional
T cells can utilize CTLA-4 in a cell-extrinsic manner in vivo
(165, 166).
In addition to exploring the role of CTLA-4, TCR-trans-
genic Tregs have also been used to study the involvement of
the TGFb pathway in Treg suppression. Although the
importance of TGFb for maintaining immune homeostasis is
unquestioned, whether Tregs need TGFb for their suppressive
function and whether conventional T cells need to perceive
TGFb to be suppressed has been unclear. Using the BDC2.5
TCR, Ishigame et al. (157) investigated the necessity of
TGFbR-mediated signals for Treg function. In this study,
BDC2.5 T cells were adoptively transferred into SCID/NOD
mice, with diabetes effectively prevented by co-transfer of
Foxp3-RFP+ BDC2.5 Tregs. Repeating these co-transfers using
the same Treg lacking TGFbRII revealed that TGFb signaling
via this receptor is not required for Treg function, as all recip-
ients remained disease-free (167). Likewise Tregs lacking
TGFbRII expression retained the capacity to regulate colitis,
resulting in colon histopathology indistinguishable from that
of mice treated with TGFbRII-sufficient Tregs (168). This dif-
fers from results seen when effector T cells were rendered
insensitive to TGFb using a dominant negative form of the
TGFbRII; in mouse models of diabetes (169) and colitis
(170), effector cells that were unable to respond to TGFb
failed to be appropriately controlled by Tregs. Curiously, in
the colitis model, when TCR-transgenic Tregs (DO11.10) that
were either sufficient or deficient for TGFb1 were compared,
no difference was observed in their ability to suppress pathol-
ogy (170) and yet suppression was abrogated by anti-TGFb
antibody in both cases. This observation suggests that success-
ful suppression of a destructive immune response by Tregs
can require TGFb even when the Tregs themselves are not
producing this cytokine. Using T cells lacking TGFbRII
expression, rather than those expressing dominant negative
TGFbRII, it was recently shown that conventional T cells do
not require the capacity to respond to TGFb signaling for sup-
pression to occur in vivo (168), mirroring results obtained
earlier using in vitro assays (171). While at face value, these
data are hard to reconcile, one possible interpretation is that
TGFb is not a direct mediator of Treg function per se but is
involved in generating an environment permissive of sup-
pression. Thus, TGFb availability would support Treg func-
tion, without being an absolute requirement for it. Since
strong TCR signaling can release T cells from Treg suppres-
sion (172, 173), the observation that TGFb decreases T-cell
sensitivity to TCR stimulation (168) could potentially be
important in this regard.
Insights into peripheral Treg induction
In addition to their valuable contribution to our understand-
ing of thymus-derived Tregs (tTregs), TCR-transgenic
systems have helped to shed light on the biology of T cells
induced to express Foxp3 in the periphery (pTreg) [for Treg
nomenclature, see Abbas et al. (174)]. The potential to start
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with a mono-specific conventional T-cell population free
from Tregs is a major advantage of such systems. In elegant
experiments that utilized the known specificity of the 5C.C7
TCR, the Allison laboratory (175) demonstrated that optimal
Foxp3 induction in adoptively transferred CD4+ T cells
occurred in response to low doses of high-affinity ligand.
Furthermore, the small population of cells that did express
Foxp3 in response to low affinity peptide was found to have
contracted by day 5 post immunization and did not persist
over the long term (175). These data mirror findings in the
thymus suggesting a requirement for relatively strong TCR
stimulation for efficient Treg generation (11).
To determine whether Tregs arose in the periphery in
response to a pancreatic self-antigen, Wong et al. (176) uti-
lized transgenic mice expressing the diabetogenic BDC2.5
TCR. Using TCR-based lineage tracing, the authors showed
that conversion from the conventional to the regulatory
T-cell compartment occurred only at very low frequencies
both within the pancreas and its draining lymph node
(176). In addressing the same question, the Ziegler labora-
tory (177) adoptively transferred naive CD4+ Foxp3 GFP
T cells from DO11.10 TCR-transgenic RAG/ bone mar-
row chimeric mice into RAG/ recipients expressing OVA
under the control of the rat insulin promoter. In this sys-
tem, any Treg occurring in recipient mice must have arisen
from Foxp3 donor cells. At 18 days post cell transfer,
Tregs were observed in both the spleen and pancreatic
lymph node, affording long-term protection against diabetes
onset (177). The contrasting results observed between these
reports are likely due to differences in the experimental sys-
tems utilized, including the presence of existing Treg popu-
lations in the BDC2.5 TCR study and the use of
lymphopenic recipients in the DO11.10 TCR study. In this
regard, it has recently been shown that thymus-derived and
peripherally induced Tregs share a common peripheral
niche, and that the former can outcompete the latter when
both are present together (178).
TCR-transgenic systems have also been used to probe the
differential characteristics of thymic-derived tTregs versus
peripherally induced pTregs. By adoptively transferring OT-
II TCR-transgenic CD4+ Foxp3 cells into congenic hosts,
the Shevach laboratory (179) demonstrated that unlike their
thymic-derived counterparts, pTregs did not express the
transcription factor Helios when induced with low-dose
OVA. However, the validity of Helios as a marker of the
tTreg population is now disputed (180–182). It has recently
been proposed that tTregs and pTregs can be effectively
distinguished based on their expression of the receptor
Neuropilin-1 (Nrp-1). To examine this possibility, two
groups used TCR-transgenic mice on a RAG-deficient back-
ground, which generate progeny lacking tTregs. Yadav et al.
(183) found that despite the lack of Tregs in the thymus,
1B3 TCR-transgenic RAG/ mice demonstrated the emer-
gence of a peripheral population of CD4+ Foxp3+ cells
within roughly 3 weeks of birth. Transcriptional analyses
comparing these Tregs with those from 1B3 TCR-transgenic
animals, which generate tTregs normally, showed lower
expression of Nrp-1 by pTregs (183). Along these same
lines, Weiss et al. (184) used DO11.10 TCR-transgenic
RAG/ mice, which similarly lack tTregs, to show that
pTregs generated in the gut mucosa in response to OVA
antigen express lower levels of Nrp-1 mRNA than the total
Tregs pool in wildtype BALB/c mice.
TCR-transgenic systems have also facilitated functional
comparison of thymus-derived Tregs and peripherally
induced Tregs. In one study, IL-10 differentiated DCs
(DC10) were used to generate induced Tregs either in vitro
or in vivo and these were directly compared with tTregs in a
model of airway inflammation (185). The presence of the
OT-II TCR transgene controlled for antigen specificity
between the different Treg populations. Following adoptive
transfer of pTregs or tTregs into recipients at day 46 post
sensitization with OVA, pTregs were found to be superior at
ameliorating airway hyper-reactivity and controlling IgE lev-
els (185). More work is required to delineate the extent to
which thymic-derived and peripherally induced Treg popu-
lations play distinct versus overlapping roles in immune
regulation.
Bypassing Treg suppression in vivo
Given the importance of Tregs in controlling the activity of
self-reactive T cells, there has been much interest in whether
defects in Treg number or function might underlie the devel-
opment of autoimmune diseases. Using a TCR-transgenic
system in which TS1 TCR+ cells induce arthritis in response
to PR8 HA expressed as a self-antigen, the Caton laboratory
(186) identified a key role for the Treg TCR repertoire in
determining the efficacy of suppression. As such, TS1 TCR+
Tregs suppressed the clonotypic Tconv that shared their spec-
ificity but failed to inhibit arthritis due to their inability to
suppress bystander T cells of different TCR specificities
(186). Along similar lines, Treg populations with a lower
TCR diversity were shown to be poorer at controlling pathol-
ogy in a model of graft-versus-host disease (187). Treg
repertoire constraint may well underlie the development of
autoimmune diseases in mice subjected to thymectomy
© 2014 The Authors. Immunological Reviews Published by John Wiley & Sons Ltd.
Immunological Reviews 259/2014 33
Attridge & Walker  Antigen-specific Treg homeostasis and function
3 days following birth (188); pTregs can be detected in
these animals (189) and have the potential to elicit regula-
tory function (190), yet they fail to prevent the emergence
of autoimmune pathology. It is now known that Treg reper-
toires undergo ‘reshaping’ in the periphery (191, 192),
likely reflecting encounter with self or environmental anti-
gens. While Treg cohorts with a lower TCR diversity are also
subject to peripheral ‘reshaping’, their lack of breadth ulti-
mately results in a heightened risk of autoimmunity (193).
Thus, conventional T-cell responses can escape appropriate
control in cases where the TCR repertoire of the Treg popu-
lation is not sufficiently diverse.
In the setting of diabetes, despite no obvious deficit of
Treg numbers (reviewed in 194), we were keen to explore
whether Tregs might be functionally impaired in diabetic
animals. Using the DO11 x rip-OVA model of type-1 diabe-
tes, we found that Tregs in diabetic animals appear to be
fully functional, even showing somewhat enhanced suppres-
sive capacity (78) (Fig. 4). We observed that conventional
CD4+ T cells (Tconv) taken from either prediabetic or dis-
eased animals induced diabetes with equivalent efficacy
when transferred into Rip-mOVA RAG/ recipients but
showed differing sensitivity to regulation. Co-transfer of
Tregs with Tconv cells from prediabetic mice was highly
successful at inhibiting diabetes but was ineffective at sup-
pressing disease induced by Tconv cells from diabetic ani-
mals (78). These data suggested that during progression to
overt diabetes, conventional T cells in this model develop
resistance to Treg-mediated suppression. Similar results from
the Mathis laboratory have shown that Tregs from NOD
mice show no defect in suppressive capacity compared to
those from wildtype animals; rather, NOD Tconv are less
prone to suppression than wildtype Tconv (195) consistent
with earlier observations in this model (196, 197).
Importantly, analysis of lymphocyte populations from Type
1 diabetes patients has confirmed that Tconv cells can
exhibit resistance to Treg suppression in this setting (198,
199).
In the DO11 9 rip-mOVA mouse model, levels of IL-21
mRNA increased in Tconv isolated from the draining pan-
creatic lymph node as this population acquired resistance to
Treg suppression (78). IL-21 was shown to interfere with
Treg suppression in vitro, and this was associated with inhibi-
tion of Tconv IL-2 production, thereby starving Tregs of a
critical survival factor (200). Interestingly, IL-21 could sub-
stitute for the lack of IL-2 in the Tconv population, permit-
ting their responses to proceed unimpaired (200). Other
reported examples of cytokines capable of counteracting
Treg suppression include IL-2 (201), IL-6 (202), IL-7 and
IL-15 (203), IL-1 and IL-18 (204), and TNFa (205). Inter-
estingly, although these cytokines utilize a variety of path-
ways to counteract suppression, IL-27 has also been shown
to impair Treg homeostasis in a similar fashion to IL-21, by
inhibiting IL-2 production in vivo (206). In other cases, cyto-
kine signaling may simply substitute for CD28 costimula-
tion, thus bypassing the need for Tconv to compete with
constitutively CTLA-4-equipped Tregs for costimulatory
ligands.
Fig. 4. Tregs from diabetic mice are functional in vivo, but conventional T cells show resistance to suppression. Conventional OVA-specific T
cells from healthy 6-week-old or diabetic 12- to 13-week-old (diab) DO11 9 rip-mOVA mice were adoptively transferred into rip-mOVA/
RAG/ recipients. Where indicated, OVA-specific Tregs from healthy or diabetic animals were co-injected. (i–iii) Tregs from diabetic mice were
highly effective at controlling diabetes; however, conventional T cells from diabetic mice showed resistance to suppression. (iv) OVA-specific T
cells that had been activated for 4 days in vitro with 1 lg/ml OVA peptide retained sensitivity to suppression, suggesting that resistance was not
simply a consequence of activation. Figure adapted from Clough et al. (78).
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Concluding remarks
The tools of modern immunology, most notably TCR
transgenesis and fate-mapping reporters (e.g. Foxp3-GFP),
have revolutionized our capacity to study Treg biology. The
key feature of both approaches is that they facilitate study of
Tregs in a physiologic setting in vivo. In particular, the
serendipitous generation of animal models in which Tregs
express transgenic TCRs has permitted analysis of cohorts of
antigen-specific Tregs responding to immunized-antigen or
tissue-expressed self-antigen in a whole animal. The lessons
that we have learned from such analyses serve to underline
the fundamental similarity between conventional and
regulatory T cells, with both populations feeding off TCR
stimulation, CD28 costimulation, and cytokine signaling. A
key difference appears to be the constitutively active state of
the Treg population, epitomized by higher levels of prolifer-
ation that presumably reflect encounter with self-antigen.
Given the remarkable proliferative capacity, site-specific
accumulation, and dynamic repertoire reshaping that charac-
terizes the Treg population in the periphery, it is somewhat
incongruous that they were initially defined as anergic. A
better understanding of the parameters that determine the
size of the peripheral Treg niche and the division of labor
between thymus-derived and peripherally derived popula-
tions should provide guidance on the best strategies to
manipulate these cells clinically.
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